CTRI/2024/03/064626
Not yet recruiting
Phase 3
Evaluation of Prophylactic Efficacy and Safety of Ayurvedic Intervention (Dashmool Taila and Bhunimbadi Kwatha) in Migraine Headache - NI
Dr Kumar Prabhat Bishnu0 sites0 target enrollmentTBD
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Dr Kumar Prabhat Bishnu
- Status
- Not yet recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients who will meet following criteria will be selected for the study.
- •a) Adult patients (aged 18\-65 years) with a diagnosis of Migraine without aura according to the International Classification of Headache Disorders 3ß (ICHD3\) criteria.
- •b) Patients with history of migraine type headache without aura for at least 1 year prior to the study and before the age of 50\.
- •c) Patients who have at least two migraine attacks per month in the last 3 months before the recruitment and not more than 15 days per month.
- •d) Participants who are medically fit for nasya karma.
- •e) Patients able to maintain a headache diary.
- •f) Patients able and willing to provide written informed consent.
- •g) No expectation that subject will be moving out of the area of the study center during the next 2 months.
Exclusion Criteria
- •Patients who will have following characteristics not be selected for the study.
- •a) Patients with a history of migraine type headache with aura.
- •b) Patients with a history of hypersensitivity to any of study medications.
- •c) Patients with abnormal vital signs, renal failure, hepatic disease, heart disease or any clinically significant systemic diseases.
- •d) Patients with headache other than migraine, severe psychiatric disease, infections and malignancy.
- •e) Patients who had taken migraine prevention drugs during the last 2 months prior to study.
- •f) Patients’ headache attacks are associated with or attributable to an identifiable cause, such as: premenstrual period; a disease of eye, ear or nose; a neurological disease; or a psychiatric illness.
- •g) Patients are diagnosed to have nasal pathologies that may interfere with the drug absorption.
- •h) Patients who will unable to continue for the proposed length of treatment or return for follow\-up visits.
- •i) Serum SGOT and SGPT, Alkaline Phosphatase, Creatinine and Total bilirubin greater than the upper limits of the normal (ULN) of the reference range at the screening assessment.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Prophylactic Effects of Levetiracetam on Migraine in 4-14 Years Old ChildreMigraine.MigraineIRCT2015101714333N44Vice chancellor for research, Kermanshah University of Medical Sciences30
Withdrawn
Not Applicable
Clinical Evaluation of Safety and Effectiveness of the BackBeat Medical Moderato System in Patients with Hypertension: A Double-Blind Randomized Trialhigh blood pressureHypertension1000752110057166NL-OMON46157BackBeat Medical, Inc.10
Recruiting
Phase 3
Assessment of the prophylactic combined effect of diphenhydramine with paracetamol on agitation and pain after laparoscopic cholecystectomyCholecystectomy.IRCT20170411033365N4Oroumia University of Medical Sciences30
Completed
Not Applicable
Prospective evaluation of efficacy and safety of argon plasma coagulation therapy with submucosal injection prior to ablation in Barrett's esophagusC15.5Lower third of oesophagusDRKS00003369HSK Wiesbaden60
Completed
Phase 3
A comparative study on the prophylactic effect of Dexmedetomidine and Paracetamol on intraoperative hemodynamic control and postoperative pain in patients undergoing laparoscopic cholecystectomyIRCT20180115038381N1Arak University of Medical Sciences132